Filing Details
- Accession Number:
- 0000899243-20-019869
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-21 19:35:42
- Reporting Period:
- 2020-07-17
- Accepted Time:
- 2020-07-21 19:35:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1807901 | Pandion Therapeutics Inc. | PAND | Pharmaceutical Preparations (2834) | 833015614 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1817416 | Rahul Kakkar | C/O Pandion Therapeutics, Inc., 134 Coolidge Avenue Watertown MA 02472 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-07-21 | 21,133 | $0.00 | 702,515 | No | 4 | C | Indirect | By Shah-Kakkar Holdings, LLC |
| Common Stock | Acquisiton | 2020-07-21 | 14,000 | $18.00 | 14,000 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By Shah-Kakkar Holdings, LLC |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2020-07-17 | 27,181 | $0.00 | 27,181 | $18.00 |
| Common Stock | Stock Option (right to buy) | Acquisiton | 2020-07-17 | 221,067 | $0.00 | 221,067 | $18.00 |
| Common Stock | Stock Option (right to buy) | Acquisiton | 2020-07-17 | 100,493 | $0.00 | 100,493 | $18.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2020-07-21 | 107,768 | $0.00 | 21,133 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 27,181 | 2030-07-16 | No | 4 | A | Direct | |
| 221,067 | 2030-07-16 | No | 4 | A | Direct | |
| 100,493 | 2030-07-16 | No | 4 | A | Direct | |
| 0 | No | 4 | C | Indirect |
Footnotes
- The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.
- This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on August 5, 2020, with the remainder of the shares vesting in equal monthly installments following August 5, 2020 through August 5, 2023, subject to the reporting person's continued service on each applicable vesting date.
- This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date.
- This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on June 25, 2021, with the remainder of the shares vesting in equal monthly installments following June 25, 2021 through June 25, 2024, subject to the reporting person's continued service on each applicable vesting date.
Billionaire Hedge Funds
